Sequence Variations of Genes in the Estrogen Pathway and Perinatal Depression
NCT ID: NCT02373709
Last Updated: 2024-11-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
750 participants
OBSERVATIONAL
2010-10-31
2028-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Clinical and Genetic Aspects of Fetuses With Sex-chromosome Disorders
NCT07304193
Next Generation to Identify Genetic Causes of Disease in Patients Participating in NICHD Clinical Protocols
NCT01375543
Evaluating Prenatal Exome Sequencing Study
NCT05290701
Genetic Variants in Nicotinamide Adenine Dinucleotide (NAD) Synthesis Pathway
NCT03799705
Clinical and Genetic Aspects in Fetuses and Children With Sex Chromosome Disorders
NCT07341412
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
A case control study will be conducted to evaluate the association of variants in estrogen receptor and related genes with the disorder in our population. Women attending antenatal and postnatal clinics will be screened with the Edinburgh Postnatal Depression Scale and cases will be identified. DNA from controls who are well throughout the antenatal and postpartum period and cases meeting DSM IV criteria for depressive disorder will be genotyped for various genetic variants. The distribution of single nucleotide polymorphisms and haplotypes and non-genetic risk factors will be compared between cases and controls and within the case group. The risk factors for postnatal depression in relation to peripartum factors such as demographic, obstetric, anaesthetic and pain outcomes will be investigated.
As perinatal depression is known to contribute to inadequate self-care and poor compliance with prenatal care, early diagnosis and treatment interventions are critical for the health and well-being of both mother and infant. In the short term, identified genetic markers that increase vulnerability to puerperal triggering of depression can be an additional screening tool to identify at-risk expectant mothers for early management during a very critical period for mother, infant, and family. In the long run, it may lead to identification of new pathways or treatment targets for this common but under-studied disorder.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cases: Perinatal depression
Cases will be defined as those with a depressive episode with onset during the antenatal or postnatal period.
No interventions assigned to this group
Controls: No perinatal depression
Controls will be defined as those who score \< 7 on Edinburgh Postnatal Depression Scale and/or no episode of clinical depression from pregnancy until 6 months postnatal.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Natural conception (not artificially assisted)
* Cases: depressive episode during antenatal period or \< 6 months postnatal at time of recruitment; patients with past diagnosis of depression must have been well for 3 months before pregnancy
* Controls: well during antenatal period or \> 6 months postnatal at time of recruitment; no family history of depression or affective disorders
Exclusion Criteria
* Previously diagnosed neurological disorders
21 Years
35 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National University Hospital, Singapore
OTHER
KK Women's and Children's Hospital
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ene Choo Tan, Ph.D.
Role: PRINCIPAL_INVESTIGATOR
KK Research Centre
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
KK Women's and Children's Hospital
Singapore, , Singapore
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2010/539/F
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.